MCA
PMCB icon

Maryland Capital Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Maryland Capital Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35
Closed -$68 – 276
2024
Q3 		$68 Buy
+35
New +$65 ﹤0.01% 241

Other funds holding PMCB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Maryland Capital Advisors's PMCB Position: Q4 2024 in Review

Maryland Capital Advisors sold out of PharmaCyte Biotech (PMCB) in Q4 2024, closing a stake of 35 shares — an estimated $68 sold.

Maryland Capital Advisors first reported a position in PMCB in Q3 2024 and held it in 1 quarter. The position peaked at $68 in Q3 2024. 21 funds tracked by Wall St. Rank hold PMCB as of Q4 2024.

  • Maryland Capital Advisors reported no remaining PharmaCyte Biotech position as of Q4 2024 after selling out during the quarter.
  • Maryland Capital Advisors sold 35 PharmaCyte Biotech shares in Q4 2024, an estimated $68.
  • Maryland Capital Advisors first reported a position in PharmaCyte Biotech in Q3 2024 and held it in 1 quarter.
  • Maryland Capital Advisors's PharmaCyte Biotech position peaked at $68 in Q3 2024.
  • 21 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2024.

Based on Maryland Capital Advisors's 13F filing for Q4 2024, filed 30 Jan 2025.